Original Article
Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn
N Engl J Med 2006; 354:579-587February 9, 2006
- Abstract
Background
Persistent pulmonary hypertension of the newborn (PPHN) is associated with substantial infant mortality and morbidity. A previous cohort study suggested a possible association between maternal use of the selective serotonin-reuptake inhibitor (SSRI) fluoxetine late in the third trimester of pregnancy and the risk of PPHN in the infant. We performed a case–control study to assess whether PPHN is associated with exposure to SSRIs during late pregnancy.
Methods
Between 1998 and 2003, we enrolled 377 women whose infants had PPHN and 836 matched control women and their infants. Maternal interviews were conducted by nurses, who were blinded to the study hypothesis, regarding medication use in pregnancy and potential confounders, including demographic variables and health history.
Results
Fourteen infants with PPHN had been exposed to an SSRI after the completion of the 20th week of gestation, as compared with six control infants (adjusted odds ratio, 6.1; 95 percent confidence interval, 2.2 to 16.8). In contrast, neither the use of SSRIs before the 20th week of gestation nor the use of non-SSRI antidepressant drugs at any time during pregnancy was associated with an increased risk of PPHN.
Conclusions
These data support an association between the maternal use of SSRIs in late pregnancy and PPHN in the offspring; further study of this association is warranted. These findings should be taken into account in decisions as to whether to continue the use of SSRIs during pregnancy.
Media in This Article
Table 1
Selected Demographic, Maternal, and Fetal Characteristics of Study Subjects.Table 2
Use of SSRIs and Other Antidepressants during Pregnancy by Mothers of Infants with PPHN and Matched Controls.Article Activity
- Article
Persistent pulmonary hypertension of the newborn (PPHN) occurs in an estimated 1 or 2 infants per 1000 live births and is associated with substantial morbidity and mortality.1-4 Despite treatment, 10 to 20 percent of affected infants will not survive.4,5 Newborns with PPHN are typically full-term or near-term infants without associated congenital anomalies who present shortly after birth with severe respiratory failure requiring intubation and mechanical ventilation.6 This disruption of the normal fetal-to-neonatal circulatory transition is characterized by postnatal persistence of elevated pulmonary vascular resistance, resulting in right-to-left shunting of blood through fetal channels (the patent ductus arteriosus, foramen ovale, or both), diminished pulmonary blood flow, and profound hypoxemia.6,7
On pathological study, newborn infants with PPHN are found to have congenital pulmonary vascular remodeling involving increased muscularization of the pulmonary arterioles. This increased muscularization may be due to distal extension of hypertrophied or hyperplastic arteriolar smooth muscle.7 Possible mechanisms leading to the maintenance of high pulmonary vascular resistance after birth may include decreased production of, or responsiveness to, vasodilators such as nitric oxide and prostacyclin; increased production of, or responsiveness to, vasoconstrictors such as endothelin and platelet-derived growth factor; or changes in the production of, or responsiveness to, both vasoconstrictors and vasodilators.8 However, structural pulmonary vascular remodeling clearly has a role in the pathogenesis of at least some cases of PPHN.
These findings suggest that prenatal exposures can contribute to the pathogenesis of this disorder. However, few studies have focused on risk factors for the development of PPHN. Male sex, nonvertex presentation, meconium staining of the amniotic fluid, neonatal sepsis, and pneumonia have been suggested as potential risk factors.6,8 Maternal risk factors include a lower educational level, fever, urinary tract infection, diabetes, cesarean section, antenatal use of nonsteroidal antiinflammatory agents (NSAIDs), and possibly tobacco use.6-10
The results of a previous small cohort study conducted by a teratogen-information service generated the hypothesis that maternal use of selective serotonin-reuptake inhibitors (SSRIs) in late pregnancy may be a risk factor for PPHN.11 Among 174 infants born to women who used fluoxetine for some portion of their pregnancies, the 73 who were exposed to fluoxetine up to the time of delivery were significantly more likely to have specific transient neonatal complications, including respiratory problems, jitteriness, and hypotonia, than the 101 infants whose prenatal exposure was restricted to the first trimester of pregnancy. Two of the 73 infants (2.7 percent) exposed to fluoxetine in late pregnancy had PPHN, as compared with none of the 101 exposed only in early pregnancy.11 We conducted a study to test the hypothesis that exposure to SSRIs during late pregnancy is associated with an increased risk of PPHN. Our study is part of a large case–control study of risk factors for PPHN, conducted within the Birth Defects Study of the Slone Epidemiology Center.
Methods
The Slone Epidemiology Center Birth Defects Study began interviewing mothers of malformed children in 1976.12 The present analyses are based on a specially designed study, nested within the Birth Defects Study, to evaluate risk factors for PPHN, with a specific focus on exposure to NSAIDs and SSRIs during late pregnancy. Study subjects from 97 institutions in four metropolitan areas (Boston; Philadelphia; San Diego, California; and Toronto) were identified between 1998 and 2003. To identify subjects, admission and discharge records from major referral hospitals and clinics were reviewed, logbooks from neonatal intensive care units were examined, and weekly telephone calls were made to collaborators at newborn nurseries in community hospitals; the calls to community hospitals were made to identify infants with PPHN who might not have been referred to major centers. Information on healthy newborns from the same centers was also collected. Prior approval for the study was obtained from the review boards of all participating institutions. All mothers who were interviewed gave oral consent and, when it was required by institutional review boards, written consent to participation in the study.
The participation rate was 69 percent for mothers of subjects with PPHN and 68 percent for mothers of controls. After exclusion of mothers who could not be located and invited to participate, the rates were 73 percent and 71 percent, respectively.
Selection of Patients and Controls
The diagnostic criteria for PPHN were a gestational age of more than 34 weeks, presentation shortly after birth with severe respiratory failure, and evidence of pulmonary hypertension. Severe respiratory failure was defined as the need for intubation and mechanical ventilation. The exclusion criteria were evidence of any cardiac anomaly except for patent ductus arteriosus, patent foramen ovale, an atrial septal defect, or a single, small, muscular ventricular septal defect. Subjects with an atrial septal defect were included because right-to-left atrial hemodynamic shunting commonly occurs among infants with PPHN, and neonatal echocardiographic studies often do not distinguish between atrial septal defects and patent foramen ovale. Infants who had isolated small muscular ventricular septal defects were not excluded, because the abnormality was thought to be a hemodynamically insignificant finding.
Pulmonary hypertension was documented either by a 5 percent or greater gradient between preductal and postductal oxygen saturation or by echocardiographic evidence. Among those who underwent echocardiography, infants were designated as having PPHN if any of the following criteria were met: the cardiologist assigned the diagnosis of PPHN or noted significant or marked pulmonary hypertension, the echocardiogram showed right-to-left hemodynamic shunting at the ductus arteriosus or at the patent foramen ovale, or the echocardiogram showed bidirectional hemodynamic shunting accompanied by leftward bowing of the ventricular septum to a degree consistent with a pulmonary arterial pressure more than half of the systemic pressure.
Records for all infants admitted to the neonatal intensive care units at participating hospitals were screened by nurses or by respiratory therapists specially trained to identify PPHN. One of the authors, a neonatologist, who was blinded to the history of maternal exposure to medications, reviewed the medical records of all patients with potential PPHN, including infants with diagnostic codes for asphyxia, cyanotic congenital heart disease, respiratory distress syndrome, pneumonia, meconium aspiration, transient tachypnea of the newborn, or pulmonary hypertension.
The control group consisted of infants born after 34 weeks of gestation without malformations who were matched with patients according to the hospital in which they were born and their date of birth (±30 days). The intended ratio of patients to controls was 1:2. After the final classification of patients with confirmed PPHN and completion of the interviews, controls who were matched with these patients and whose mothers had completed the interview were selected for the analyses.
Assessment of Exposure
Within six months of delivery, trained study nurses who were unaware of the study hypothesis interviewed the mothers of the patients and the mothers of the control infants. The telephone interview was detailed and structured, and it included questions on demographic characteristics, the mother's medical and obstetrical history, the parents' habits and occupations, and the use of all medications (prescription and over-the-counter) during the period from two months before conception to the end of the pregnancy. The interviewer entered the mother's responses directly into the computer. During the interview, the interviewer had access to computerized dictionaries of drugs and diagnoses, and responses were instantaneously coded. Quality-control procedures were conducted both manually and by computer.
The mothers were asked whether they had taken any medication for depression. A list of specific antidepressant drugs was read to each mother. Any report of medication use prompted a systematic series of questions, including the brand or generic name of the drug, the indication for which it was prescribed, the form and size of the dose, the starting and stopping dates, the frequency of dosing, and the number of pills taken per day. Recall of the timing of use was enhanced by the use of a calendar that highlighted the date of the woman's last menstrual period and the delivery date.
We classified antidepressants either as SSRIs or as other antidepressants. To be consistent with our hypothesis, we defined late-pregnancy exposure as the use of an antidepressant at any time in the second half of gestation (from 20 completed weeks after the first day of the last menstrual period until the date of delivery).
Statistical Analysis
Multivariate conditional logistic regression was used to estimate prevalence odds ratios (which approximate relative risks for rare outcomes) and 95 percent confidence intervals for PPHN in relation to antidepressant exposure. Risk estimates were adjusted for potential confounders. The analyses were performed with SAS for Windows (version 8.2).
Results
We enrolled 637 infants with possible PPHN; the diagnosis was confirmed in 377 of the infants, 12 of whom (3.2 percent) were born after a multiple pregnancy. These 377 patients were matched with 836 controls, 17 of whom (2.0 percent) were born after a multiple pregnancy, for a case–control ratio of 1:2.2. Of the 377 patients, 60 were preterm (born after a gestation period of >34 through <37 weeks). Among infants born at term, 265 were born with a patent ductus arteriosus. The frequency of infant death up to the time of the maternal interview was 3.0 percent in the PPHN group and 0 percent in the control group.
The specific SSRI medications that study participants reported using were citalopram, fluoxetine, paroxetine, and sertraline. Among non-SSRI antidepressants, participants reported using tricyclic antidepressants (namely, amitriptyline, imipramine, and nortriptyline), bupropion, venlafaxine, and trazodone.
Maternal factors significantly associated with PPHN in unadjusted analyses included lower educational level, black or Asian race, higher prepregnancy body-mass index (the weight in kilograms divided by the square of the height in meters), and diabetes mellitus; male infants also had increased risk (Table 1Table 1
Selected Demographic, Maternal, and Fetal Characteristics of Study Subjects.). The factors associated in unadjusted analyses with SSRI use in the control group included tobacco and alcohol use, maternal diabetes, a body-mass index of more than 27, and white race (data not shown). These factors have previously been associated with the use of antidepressants.13,14 Table 2Table 2
Use of SSRIs and Other Antidepressants during Pregnancy by Mothers of Infants with PPHN and Matched Controls. presents the matched odds ratios and 95 percent confidence intervals for antidepressant use relative to no antidepressant use during pregnancy. The crude risk of PPHN associated with the use of any antidepressant at any time in pregnancy was not significantly elevated (odds ratio, 1.3; 95 percent confidence interval, 0.7 to 2.2), nor was the use of SSRIs alone at any time in pregnancy significantly associated with PPHN (odds ratio, 1.5; 95 percent confidence interval, 0.8 to 2.9). However, when the comparison was stratified according to the timing of exposure in pregnancy, use of any antidepressant after the 20th week of gestation was significantly associated with PPHN (odds ratio, 2.9; 95 percent confidence interval, 1.3 to 6.5). Further analysis demonstrated that this association was entirely attributable to the subgroup of infants with late exposure to SSRIs (odds ratio for SSRI use after the 20th week of gestation relative to no use in the pregnancy, 5.1; 95 percent confidence interval, 1.9 to 13.3). There was no increased risk of PPHN when SSRI use was restricted to the first half of the pregnancy (odds ratio, 0.3; 95 percent confidence interval, 0.1 to 1.1).Adjustment in a multivariate analysis for maternal diabetes (pregestational or gestational, with or without treatment), maternal race or ethnic group, and body-mass index did not attenuate the association between exposure to SSRIs late in pregnancy and PPHN, which remained significantly elevated (adjusted odds ratio, 6.1; 95 percent confidence interval, 2.2 to 16.8) (Table 2). Inclusion of other factors in the multivariate model, such as use of NSAIDs in late pregnancy, smoking, and alcohol intake, did not substantially change the results (data not shown). The proportion of SSRI-exposed women taking another psychoactive drug in the second half of the pregnancy was similar for mothers of patients (29 percent) and mothers of controls (33 percent). Furthermore, restriction of analyses to full-term births (infants born at 37 weeks of gestation or later) resulted in a similar estimate of the odds ratio (adjusted odds ratio, 5.6; 95 percent confidence interval, 2.0 to 15.4). The association was also similar for patients with and without patent ductus arteriosus and after exclusion of mothers whose infants died (data not shown).
Although our predefined cutoff point for exposure in late pregnancy was 20 weeks of gestation, 12 of the 14 mothers with late SSRI exposure whose infants had PPHN continued use of their medication at least into the eighth month of pregnancy. Post hoc analysis using a cutoff point of 26 weeks of gestation yielded identical results (adjusted odds ratio, 6.1; 95 percent confidence interval, 2.2 to 16.8). The numbers were too small to permit examination of the effects of dose size, specific SSRI used, or reduction of the length of exposure before delivery.
Discussion
This large case–control epidemiologic study focusing on risk factors for PPHN showed a significant association between exposure of a mother to an SSRI during late pregnancy and the occurrence of PPHN in her infant. This finding is consistent with an earlier observation in a small cohort study.11
Although our study cannot establish causality, several possible mechanisms suggest that a causal association is plausible. The lung acts as a reservoir for antidepressant drugs, and substantial accumulation of SSRIs in the lungs has been reported.15,16 Serotonin not only has vasoconstrictive properties that increase pulmonary vascular resistance,17 but also has mitogenic and comitogenic effects on pulmonary smooth-muscle cells.18,19 Thus, higher circulating levels of serotonin in the fetus and accumulation of serotonin in the fetal lung might result in the proliferation of smooth-muscle cells that is characteristic of PPHN.
Another potential pathway is through the inhibitory effect of SSRIs on the synthesis of nitric oxide, a vasodilator that appears to have a role in the regulation of vascular tone and reactivity both in utero and during postnatal life.7 In one study, the release of nitric oxide was inhibited in a dose-dependent fashion in synovial-cell culture medium treated with fluoxetine.20 In a sample of patients with cardiac disease who were treated with paroxetine, the activity of nitric oxide synthase was inhibited and the serum levels of nitrite and nitrate were significantly decreased as compared with pretreatment levels.21
Our findings may be consistent with some of the transient neonatal complications noted to occur in 20 to 30 percent of newborns with late prenatal exposure to SSRIs.11,22-28 Mild respiratory distress, transient tachypnea of the newborn, failure to cry, and cyanosis are among the complications that are reported with increased frequency.11,23,24,27,28 It is possible that these respiratory problems represent the less severe end of the spectrum in a range of outcomes consistent with PPHN.
We found a nonsignificant reduction in the risk of PPHN when SSRI exposure was limited to the first half of gestation; however, this estimate was based on only two exposed patients. Our study was specifically designed to assess the association of PPHN with SSRI use in the second half of pregnancy. An alternative explanation for our results is confounding, particularly confounding by indication. However, exposure to non-SSRI antidepressants was not associated with PPHN, nor was there an association between PPHN and SSRIs when exposure was limited to the first half of gestation; these observations suggest that maternal depression was not independently associated with PPHN. Controlling for other potential confounders, including maternal body-mass index, smoking, use of NSAIDs in late pregnancy, and diabetes, did not attenuate the association between SSRI use in late pregnancy and PPHN. Although residual confounding cannot be ruled out, we believe it is unlikely that it could account for an elevated risk of this size. On the other hand, it is important to note that our findings, although statistically significant, are based on a relatively small number of exposed mothers with affected infants.
A potential limitation of this study is the retrospective design, which introduces the possibilities of inaccurate recall or recall bias. However, all interviews were conducted within six months after delivery, antidepressants are prescription medications taken over the long term, and the study interviewers specifically and similarly questioned both mothers of patients and mothers of controls regarding their use of antidepressants.29 The likelihood of recall bias is reduced by the fact that neither the interviewers nor the mothers were aware of the study hypothesis at the time of the interview.30 In addition, it seems implausible that there would be differential recall of the gestational timing of exposure to SSRIs and that of exposure to other antidepressants.
It is important to replicate these findings in other studies. In addition, further research should assess the relationship of different types and dosages of SSRIs with PPHN and with milder respiratory complications in newborns. Studies should also be undertaken to investigate whether there is any association between SSRIs and PPHN in the offspring of women who discontinue SSRI use late in pregnancy. Furthermore, to better identify patients who may be at risk, investigations should explore interactions between environmental and genetic factors, the latter including polymorphisms affecting the production or regulation of enzymes involved in the metabolism of SSRIs,26 as well as mutations related to PPHN.
The prevalence of major depressive disorders among women of reproductive age is estimated to be between 10 and 15 percent.31 SSRIs are among the most common medications used to treat these disorders,32,33 and continued treatment may be needed throughout pregnancy for the health of the mother.34 Our findings might be factored into an assessment of the benefit and risk for a particular mother. On the assumption that the relative risk of 6.1 for PPHN observed in our study is true, and that the relation is causal, the absolute risk among those who use SSRIs late in pregnancy is relatively low (about 6 to 12 per 1000 women); to put it in other terms, about 99 percent of women exposed to one of these medications late in pregnancy will deliver an infant unaffected by PPHN. Pending further studies to confirm these findings, clinicians and their patients must consider both the benefits of SSRIs in the treatment of depression and the potential risk of PPHN relative to the risks and benefits of alternative treatments or nontreatment.
Supported by a grant (HL50763) from the National Heart, Lung, and Blood Institute and by the National Center for Birth Defects Research and Prevention and the Massachusetts Department of Public Health.
Dr. Chambers and Dr. Jones report having received research support from Apotex, Barr Laboratories, Par Pharmaceutical, Teva Pharmaceuticals, and Sandoz; Dr. Louik and Dr. Werler, research support from GlaxoSmithKline; and Dr. Mitchell, research support from GlaxoSmithKline, Barr Laboratories, and Genpharm. No other potential conflict of interest relevant to this article was reported.
We are indebted to Dawn Jacobs, R.N., M.P.H., Rachel Wilson, M.P.H., Fiona Rice, M.P.H., Rita Krolak, R.N., Sally Perkins, R.N., Kathleen Sheehan, R.N., Karen Bennett Mark, R.N., Deborah Kasindorf, R.N., Clare Coughlin, R.N., Geraldine Ellison, R.N., Joan Shander, Diane Gallagher, Nastia Dynkin, Nancy Rodriquez-Sheridan, Cecelia Stadler, Meghan Malone-Moses, Irene Shephard, R.N., Melody Kisor, Dawn Taggett, M.P.H., Sherlonda Allen, Michelle Hose, R.N., Beth Smith, R.N., Patricia Maloney, R.N., Merianne Mitchell, R.T., Valerie Hillis, Steven Rivers, and John Farrell for their assistance in data collection and computer programming. We also thank the medical and nursing staff of the following participating hospitals. Boston area: Baystate Medical Center, Beth Israel Deaconess Medical Center, Boston Medical Center, Brigham and Women's Hospital, Brockton Hospital, Cambridge Hospital, Caritas Good Samaritan Medical Center, Charlton Memorial Hospital, Children's Hospital, Emerson Hospital, Falmouth Hospital, Haverhill–Hale Hospital, Jordan Hospital, Kent Hospital, Lawrence General Hospital, Lowell General Hospital, Melrose–Wakefield Hospital, Metro West Medical Center–Framingham, Mt. Auburn Hospital, New England Medical Center, Newton–Wellesley Hospital, North Shore Medical Center, Rhode Island Hospital, Saints Memorial Medical Center, South Shore Hospital, Southern New Hampshire Medical Center, St. Elizabeth's Medical Center, St. Luke's Hospital, St. Vincent Hospital, UMass Memorial Health Care, and Women and Infants' Hospital. Philadelphia area: Abington Memorial Hospital, Albert Einstein Medical Center, Alfred I. duPont Hospital for Children, Bryn Mawr Hospital, Chester County Hospital, Children's Hospital of Philadelphia, Christiana Care Health Services, Community Hospital of Lancaster, Crozer–Chester Medical Center, Doylestown Hospital, Frankford Hospital, Hahnemann University Hospital, the Hospital of the University of Pennsylvania, Lankenau Hospital, Lancaster General Hospital, Lehigh Valley Hospital, Nanticoke Memorial Hospital, Pennsylvania Hospital, Sacred Heart Hospital, St. Christopher's Hospital for Children, St. Mary Medical Center, Temple University Health Sciences Center, Reading Hospital and Medical Center, and Thomas Jefferson University Hospital. Toronto area: Grand River Hospital, Guelph General Hospital, Hamilton Health Sciences Corporation, the Hospital for Sick Children, Humber River Regional Hospital–Church Site, Humber River Regional Hospital–Finch Site, Joseph Brant Memorial Hospital, Lakeridge Health Corporation, London Health Sciences Center, Mt. Sinai Hospital, North York General Hospital, Oakville Trafalgar Memorial Hospital, Scarborough Hospital–General Division, Scarborough Hospital–Grace Division, St. Joseph's Health Centre–London, St. Joseph's Health Centre–Toronto, St. Joseph's Healthcare–Hamilton, St. Michael's Hospital, Sunnybrook and Women's College Health Sciences Center, Toronto East General Hospital, Toronto General Hospital, Trillium Health Center, William Osler Heath Centre, York Central Hospital, and York County Hospital. San Diego area: Alvarado Hospital, Balboa Naval Medical Center, Camp Pendleton Naval Hospital, Children's Hospital and Health Center, Kaiser Zion Medical Center, Palomar Medical Center, Pomerado Hospital, Scripps Memorial Hospital–Encinitas, Scripps Memorial Hospital–Chula Vista, Scripps Memorial Hospital–La Jolla, Scripps Mercy Hospital, SharpChula Vista Hospital, Sharp Coronado Hospital, Sharp Grossmont Hospital, Sharp Mary Birch Hospital, Tri-City Medical Center, and UCSD Medical Center.
Source Information
From the Departments of Pediatrics (C.D.C., K.L.J.) and Family and Preventive Medicine (C.D.C.), University of California, San Diego, La Jolla; the Slone Epidemiology Center, Boston University School of Public Health, Boston (S.H.-D., M.M.W., C.L., A.A.M.); and Children's Hospital and Brigham and Women's Hospital, Harvard Medical School, Boston (L.J.V.M.).
Address reprint requests to Dr. Chambers at the University of California, San Diego, Medical Center, 200 W. Arbor Dr., Mail Code 8446, San Diego, CA 92103, or at chchambers@ucsd.edu.
- References
References
1
Farrow KN ,Fliman P ,Steinhorn RH . The diseases treated with ECMO: focus on PPHN. Semin Perinatol 2005;29:8-14
CrossRef | Web of Science | Medline2
John E ,Roberts V ,Burnard E . Persistent pulmonary hypertension of the newborn treated with hyperventilation: clinical features and outcome. Aust Paediatr J 1988;24:357-361
Medline3
Hageman JR ,Adams MA ,Gardner TH . Persistent pulmonary hypertension of the newborn: trends in incidence, diagnosis, and management. Am J Dis Child 1984;138:592-595
Web of Science | Medline4
Walsh-Sukys MC ,Tyson JE ,Wright LL , et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 2000;105:14-20
CrossRef | Web of Science | Medline5
Fricker J . Nitric oxide may reduce need for extracorporeal membrane oxygenation. Lancet 1996;347:1397-1397
CrossRef | Web of Science6
Van Marter LJ ,Leviton A ,Allred EN , et al. Persistent pulmonary hypertension of the newborn and smoking and aspirin and nonsteroidal anti-inflammatory drug consumption during pregnancy. Pediatrics 1996;97:658-663
Web of Science | Medline7
Abman SH . New developments in the pathogenesis and treatment of neonatal pulmonary hypertension. Pediatr Pulmonol Suppl 1999;18:201-204
CrossRef | Medline8
Dakshinamurti S . Pathophysiologic mechanisms of persistent pulmonary hypertension of the newborn. Pediatr Pulmonol 2005;39:492-503
CrossRef | Web of Science | Medline9
Reece EA ,Moya F ,Yazigi R , et al. Persistent pulmonary hypertension: assessment of perinatal risk factors. Obstet Gynecol 1987;70:696-700
Web of Science | Medline10
Bearer C ,Emerson RK ,O'Riordan MA ,Roitman E ,Shackleton C . Maternal tobacco smoke exposure and persistent pulmonary hypertension of the newborn. Environ Health Perspect 1997;105:202-206
CrossRef | Web of Science | Medline11
Chambers CD ,Johnson KA ,Dick LM ,Felix RJ ,Jones KL . Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996;335:1010-1015
Full Text | Web of Science | Medline12
Mitchell AA ,Rosenberg L ,Shapiro S ,Slone D . Birth defects related to Bendectin use in pregnancy. I. Oral clefts and cardiac defects. JAMA 1981;245:2311-2314
CrossRef | Web of Science | Medline13
Hasler G ,Pine DS ,Gamma A , et al. The associations between psychopathology and being overweight: a 20-year prospective study. Psychol Med 2004;34:1047-1057
CrossRef | Web of Science | Medline14
Wisner KL ,Gelenberg AJ ,Leonard H ,Zarin D ,Frank E . Pharmacologic treatment of depression during pregnancy. JAMA 1999;282:1264-1269
CrossRef | Web of Science | Medline15
Suhara T ,Sudo Y ,Yoshida K , et al. Lung as reservoir for antidepressants in pharmacokinetic drug interactions. Lancet 1998;351:332-335
CrossRef | Web of Science | Medline16
Lemberger L ,Bergstrom RF ,Wolen RL ,Farid NA ,Enas GG ,Aronoff GR . Fluoxetine: clinical pharmacology and physiologic disposition. J Clin Psychiatry 1985;46:14-19
Web of Science | Medline17
McMahon TJ ,Hood JS ,Nossaman BD ,Kadowitz PJ . Analysis of responses to serotonin in the pulmonary vascular bed of the cat. J Appl Physiol 1993;75:93-102
Web of Science | Medline18
Runo JR ,Loyd JE . Primary pulmonary hypertension. Lancet 2003;361:1533-1544
CrossRef | Web of Science | Medline19
Eddahibi S ,Raffestin B ,Hamon M ,Adnot S . Is the serotonin transporter involved in the pathogenesis of pulmonary hypertension? J Lab Clin Med 2002;139:194-201
CrossRef | Medline20
Yaron I ,Shirazi I ,Judovich R ,Levartovsky D ,Caspi D ,Yaron M . Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and synovial tissue cultures. Arthritis Rheum 1999;42:2561-2568
CrossRef | Web of Science | Medline21
Finkel MS ,Laghrissi-Thode F ,Pollock BG ,Rong J . Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol Bull 1996;32:653-658
Medline22
Nordeng H ,Lindemann R ,Perminov KV ,Reikvam A . Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr 2001;90:288-291
CrossRef | Web of Science | Medline23
Costei AM ,Kozer E ,Ho T ,Ito S ,Koren G . Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002;156:1129-1132
Web of Science | Medline24
Kallen B . Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004;158:312-316
CrossRef | Web of Science | Medline25
Zeskind PS ,Stephens LE . Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004;113:368-375
CrossRef | Web of Science | Medline26
Laine K ,Kytola J ,Bertilsson L . Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy. Ther Drug Monit 2004;26:685-687
CrossRef | Web of Science | Medline27
Sanz EJ ,De-las-Cuevas C ,Kiunu K ,Bate A ,Edwards R . Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005;365:482-487
Web of Science | Medline28
Moses-Kolko EL ,Bogen D ,Perel J , et al. Neonatal signs after in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005;293:2372-2383
CrossRef | Web of Science | Medline29
Mitchell AA ,Cottler LB ,Shapiro S . Effect of questionnaire design on recall of drug exposure in pregnancy. Am J Epidemiol 1986;123:670-676
Web of Science | Medline30
Hernan MA ,Hernandez-Diaz S ,Werler MM ,Mitchell AA . Causal knowledge as a prerequisite for confounding evaluation: an application to birth defects epidemiology. Am J Epidemiol 2002;155:176-184
CrossRef | Web of Science | Medline31
Blazer DG ,Kessler RC ,McGonagle KA ,Swartz MS . The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am J Psychiatry 1994;151:979-986
Web of Science | Medline32
Kaufman DW ,Kelly JP ,Rosenberg L ,Anderson TE ,Mitchell AA . Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002;287:337-344
CrossRef | Web of Science | Medline33
Andrade SE ,Gurwitz JH ,Davis RL , et al. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004;191:398-407
CrossRef | Web of Science | Medline34
Moses-Kolko EL ,Roth EK . Antepartum and postpartum depression: healthy mom, healthy baby. J Am Med Womens Assoc 2004;59:181-191
Medline
- Citing Articles (185)
Citing Articles
1
Heather M. Byers, John M. Dagle, Jonathan M. Klein, Kelli K. Ryckman, Erin L. McDonald, Jeffrey C. Murray, Kristi S. Borowski. (2012) Variations in CRHR1 are associated with persistent pulmonary hypertension of the newborn. Pediatric Research 71:2, 162-167
CrossRef2
Ken Lim, Ari Sanders, Ursula Brain, Wayne Riggs, Tim F. Oberlander, Dan Rurak. (2012) Third trimester fetal pulmonary artery Doppler blood flow velocity characteristics following prenatal selective serotonin reuptake inhibitor (SSRI) exposure. Early Human Development
CrossRef3
Luke E. Grzeskowiak, Andrew L. Gilbert, Janna L. Morrison. (2012) Investigating Outcomes Associated with Medication Use During Pregnancy: A review of methodological challenges and observational study designs. Reproductive Toxicology
CrossRef4
René Ernst Nielsen, Per Damkier. (2012) Pharmacological treatment of unipolar depression during pregnancy and breast-feeding—A clinical overview. Nordic Journal of Psychiatry1-8
CrossRef5
Orna Diav-Citrin, Asher Ornoy. (2012) Selective Serotonin Reuptake Inhibitors in Human Pregnancy: To Treat or Not to Treat?. Obstetrics and Gynecology International 2012, 1-12
CrossRef6
James A. Taylor, Jeffrey A. Wright, David Woodrum. 2012. Routine Newborn Care. , 300-315.
CrossRef7
Robin H. Steinhorn, Steven H. Abman. 2012. Persistent Pulmonary Hypertension. , 732-740.
CrossRef8
Thomas F. Kelly, Thomas R. Moore. 2012. Maternal Medical Disorders of Fetal Significance. , 92-104.
CrossRef9
Cynthia M. Nijenhuis, Peter G. J. ter Horst, Lolkje T. W. de Jong-van den Berg, Bob Wilffert. (2012) Disturbed development of the enteric nervous system after in utero exposure of selective serotonin re-uptake inhibitors and tricyclic antidepressants. Part 1: Literature review. British Journal of Clinical Pharmacology 73:1, 16-26
CrossRef10
Preeyaporn Sarangarm, Bonnie Young, William Rayburn, Pallavi Jaiswal, Melanie Dodd, Sharon Phelan, Ludmila Bakhireva. (2012) Agreement between self-report and prescription data in medical records for pregnant women. Birth Defects Research Part A: Clinical and Molecular Teratologyn/a-n/a
CrossRef11
Megan Galbally, Martien Snellen, Andrew J. Lewis. (2011) A review of the use of psychotropic medication in pregnancy. Current Opinion in Obstetrics and Gynecology 23:6, 408-414
CrossRef12
Avinash S. Patil, Jeffrey A. Kuller, Eleanor H. J. Rhee. (2011) Antidepressants in Pregnancy: A Review of Commonly Prescribed Medications. Obstetrical & Gynecological Survey 66:12, 777-787
CrossRef13
S. Berger, K.-J. Bär. (2011) Seelische Erkrankungen in der Schwangerschaft. Der Gynäkologe
CrossRef14
Luke E. Grzeskowiak, Andrew L. Gilbert, Janna L. Morrison. (2011) Investigating Outcomes Following the Use of Selective Serotonin Reuptake Inhibitors for Treating Depression in Pregnancy. Drug Safety 34:11, 1027-1048
CrossRef15
Kathryn L. Ponder, Amy Salisbury, Bethany McGonnigal, Alyse Laliberte, Barry Lester, James F. Padbury. (2011) Maternal depression and anxiety are associated with altered gene expression in the human placenta without modification by antidepressant use: Implications for fetal programming. Developmental Psychobiology 53:7, 711-723
CrossRef16
Laura Lorenzo, Barbara Byers, Adrienne Einarson. (2011) Antidepressant use in pregnancy. Expert Opinion on Drug Safety 10:6, 883-889
CrossRef17
Madeleine A. Becker, Tal E. Weinberger, Lex Denysenko, Elisabeth J. S. Kunkel. 2011. Mood disorders. , 138-152.
CrossRef18
Stewart, Donna E., . (2011) Depression during Pregnancy. New England Journal of Medicine 365:17, 1605-1611
Full Text19
Mukti Sharma, Karthik Ram Mohan, Shankar Narayan, Lokesh Chauhan. (2011) Persistent pulmonary hypertension of the newborn: a review. Medical Journal Armed Forces India 67:4, 348-353
CrossRef20
Maria Klara Frey, Irene Lang. (2011) Pulmonale Hypertension. Wiener klinische Wochenschrift Education 6:3, 78-93
CrossRef21
Eduard J H Mulder, Frédérique FT Ververs, Roel de Heus, Gerard H A Visser. (2011) Selective Serotonin Reuptake Inhibitors Affect Neurobehavioral Development in the Human Fetus. Neuropsychopharmacology 36:10, 1961-1971
CrossRef22
Élisabeth Autret-Leca, Hawaré Cissoko, Annie Pierre Jonville-Béra. (2011) Risque néonatal des médicaments pris à la fin de la grossesse. Thérapie 66:5, 431-436
CrossRef23
Regina C. Casper, Allyson A. Gilles, Barry E. Fleisher, Joan Baran, Gregory Enns, Laura C. Lazzeroni. (2011) Length of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: effects on neonatal adaptation and psychomotor development. Psychopharmacology 217:2, 211-219
CrossRef24
Melissa A. Parisi, Catherine Y. Spong, Anne Zajicek, Alan E. Guttmacher. (2011) We don't know what we don't study: The case for research on medication effects in pregnancy. American Journal of Medical Genetics Part C: Seminars in Medical Genetics 157:3, 247-250
CrossRef25
Martha M. Werler, Carol Louik, Allen A. Mitchell. (2011) Case-control studies for identifying novel teratogens. American Journal of Medical Genetics Part C: Seminars in Medical Genetics 157:3, 201-208
CrossRef26
Tammie B. Howard, Melissa S. Tassinari, Karen B. Feibus, Lisa L. Mathis. (2011) Monitoring for teratogenic signals: Pregnancy registries and surveillance methods. American Journal of Medical Genetics Part C: Seminars in Medical Genetics 157:3, 209-214
CrossRef27
Alok Banga, Venkatesh Handratta, Lobna Ibrahim, Daniel F. Connor. (2011) SSRIs and placental dysfunction. Medical Hypotheses 77:2, 311-312
CrossRef28
J.D.A. Olivier, T. Blom, T. Arentsen, J.R. Homberg. (2011) The age-dependent effects of selective serotonin reuptake inhibitors in humans and rodents: A review. Progress in Neuro-Psychopharmacology and Biological Psychiatry 35:6, 1400-1408
CrossRef29
Scott Patten, Sophie Grigoriadis, Serge Beaulieu. (2011) Clinical effectiveness, construct and assessment. Journal of Affective Disorders 132, S3-S8
CrossRef30
Cynthia M. Nijenhuis, Peter G.J. ter Horst, Nienke van Rein, Bob Wilffert, Lolkje T.W. de Jong-van den Berg. (2011) Disturbed development of the enteric nervous system after in utero exposure of selective serotonin reuptake inhibitors and tricyclic antidepressants. British Journal of Clinical Pharmacologyno-no
CrossRef31
Mark J. Airhart, Deborah H. Lee, Tracy D. Wilson, Barney E. Miller, Merry N. Miller, Richard G. Skalko, Paul J. Monaco. (2011) Adverse effects of serotonin depletion in developing zebrafish. Neurotoxicology and Teratology
CrossRef32
Lynette C. Daws, Georgianna G. Gould. (2011) Ontogeny and regulation of the serotonin transporter: Providing insights into human disorders. Pharmacology & Therapeutics 131:1, 61-79
CrossRef33
Laura H. Choate, Gary G. Gintner. (2011) Prenatal Depression: Best Practice Guidelines for Diagnosis and Treatment. Journal of Counseling & Development 89:3, 373-381
CrossRef34
P.G.J. ter Horst, S. van der Linde, J.P. Smit, J. den Boon, R.A. van Lingen, F.G.A. Jansman, L.T.W. De Jong-van den Berg, B. Wilffert. (2011) Clomipramine concentration and withdrawal symptoms in ten neonates. British Journal of Clinical Pharmacologyno-no
CrossRef35
DAN RURAK, KEN LIM, ARI SANDERS, URSULA BRAIN, WAYNE RIGGS, TIM F. OBERLANDER. (2011) Third Trimester Fetal Heart Rate and Doppler Middle Cerebral Artery Blood Flow Velocity Characteristics During Prenatal Selective Serotonin Reuptake Inhibitor Exposure. Pediatric Research 70:1, 96-101
CrossRef36
Ariela Frieder. (2011) Antidepressant use during pregnancy. Expert Review of Obstetrics & Gynecology 6:3, 285-294
CrossRef37
2011. References. , 209-234.
CrossRef38
Riccardo Davanzo, Marco Copertino, Angela De Cunto, Federico Minen, Alessandro Amaddeo. (2011) Antidepressant Drugs and Breastfeeding: A Review of the Literature. Breastfeeding Medicine 6:2, 89-98
CrossRef39
Kimberly Ann Yonkers, Simone Vigod, Lori E. Ross. (2011) Diagnosis, Pathophysiology, and Management of Mood Disorders in Pregnant and Postpartum Women. Obstetrics & Gynecology 117:4, 961-977
CrossRef40
Ilona Sluiter, Irwin Reiss, Ulrike Kraemer, Ronald de Krijger, Dick Tibboel, Robbert J Rottier. (2011) Vascular abnormalities in human newborns with pulmonary hypertension. Expert Review of Respiratory Medicine 5:2, 245-256
CrossRef41
Edeltraut Garbe, Marc Suling, Sebastian Kloss, Christina Lindemann, Ulrike Schmid. (2011) Linkage of mother-baby pairs in the German Pharmacoepidemiological Research Database. Pharmacoepidemiology and Drug Safety 20:3, 258-264
CrossRef42
Lyn Colvin, Linda Slack-Smith, Fiona J. Stanley, Carol Bower. (2011) Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. Birth Defects Research Part A: Clinical and Molecular Teratology 91:3, 142-152
CrossRef43
Tiffany Field. (2011) Prenatal depression effects on early development: A review. Infant Behavior and Development 34:1, 1-14
CrossRef44
Deborah R. Kim, Neill Epperson, Emmanuelle Paré, Juan M. Gonzalez, Samuel Parry, Michael E. Thase, Pilar Cristancho, Mary D. Sammel, John P. O'Reardon. (2011) An Open Label Pilot Study of Transcranial Magnetic Stimulation for Pregnant Women with Major Depressive Disorder. Journal of Women's Health 20:2, 255-261
CrossRef45
Robin Steinberg-Epstein, Teri Book, Sharon B. Wigal. (2011) Controversies Surrounding Pediatric Psychopharmacology. Advances in Pediatrics 58:1, 153-179
CrossRef46
Lewis B. Holmes. (2011) Human teratogens: Update 2010. Birth Defects Research Part A: Clinical and Molecular Teratology 91:1, 1-7
CrossRef47
Salvatore Gentile. (2011) Drug treatment for mood disorders in pregnancy. Current Opinion in Psychiatry 24:1, 34-40
CrossRef48
Satyan Lakshminrusimha, Vasanth H. Kumar. 2011. Diseases of Pulmonary Circulation. , 632-656.
CrossRef49
Stephen A Contag, Cheryl Bushnell. (2010) Contemporary management of migrainous disorders in pregnancy. Current Opinion in Obstetrics and Gynecology 22:6, 437-445
CrossRef50
O. Chatillon, C. Even. (2010) La dépression de l’antepartum : prévalence, diagnostic, traitement. L'Encéphale 36:6, 443-451
CrossRef51
Kristin J. Weaver, Ian A. Paul, Rick C.S. Lin, Kimberly L. Simpson. (2010) Neonatal Exposure to Citalopram Selectively Alters the Expression of the Serotonin Transporter in the Hippocampus: Dose-Dependent Effects. The Anatomical Record: Advances in Integrative Anatomy and Evolutionary Biology 293:11, 1920-1932
CrossRef52
Robert Keers, Katherine J. Aitchison. (2010) Gender differences in antidepressant drug response. International Review of Psychiatry 22:5, 485-500
CrossRef53
M. Reis, B. Källén. (2010) Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychological Medicine 40:10, 1723-1733
CrossRef54
Samuel Bauer, Catherine Monk, Mark Ansorge, Cynthia Gyamfi, Michael Myers. (2010) Impact of antenatal selective serotonin reuptake inhibitor exposure on pregnancy outcomes in mice. American Journal of Obstetrics and Gynecology 203:4, 375.e1-375.e4
CrossRef55
Ellen Flynn, Carmen Monzon, Teri Pearlstein. 2010. Acute Psychiatric Conditions in Pregnancy. , 684-698.
CrossRef56
Alfredo F. Gei, Victor R. Suarez. 2010. Overdose, Poisoning and Envenomation During Pregnancy. , 514-558.
CrossRef57
Stephen A. Stayer, Yang Liu. (2010) Pulmonary hypertension of the newborn. Best Practice & Research Clinical Anaesthesiology 24:3, 375-386
CrossRef58
Y J Blumenfeld, M F Reynolds-May, R B Altman, Y Y El-Sayed. (2010) Maternal–fetal and neonatal pharmacogenomics: a review of current literature. Journal of Perinatology 30:9, 571-579
CrossRef59
Marian K. Bakker, Hermien E. K. De Walle, Bob Wilffert, Lolkje T. W. de Jong-Van Den Berg. (2010) Fluoxetine and infantile hypertrophic pylorus stenosis: a signal from a birth defects-drug exposure surveillance study. Pharmacoepidemiology and Drug Safety 19:8, 808-813
CrossRef60
Christian L Hermansen. (2010) Transient tachypnea of the newborn: common in the nursery, implications for beyond. Pediatric Health 4:4, 427-431
CrossRef61
Orit Avni-Barron, Kelly Hoagland, Christina Ford, Laura J Miller. (2010) Preconception planning to reduce the risk of perinatal depression and anxiety disorders. Expert Review of Obstetrics & Gynecology 5:4, 421-435
CrossRef62
Christopher Tjoa, Emmanuelle Pare, Deborah R Kim. (2010) Unipolar depression during pregnancy: nonpharmacologic treatment options. Women's Health 6:4, 565-576
CrossRef63
Teri Pearlstein, Jami Star. 2010. Psychiatric Disorders in Pregnancy. , 524-552.
CrossRef64
W. Warburton, C. Hertzman, T. F. Oberlander. (2010) A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health. Acta Psychiatrica Scandinavica 121:6, 471-479
CrossRef65
S. Favrelière, A. Nourrisson, N. Jaafari, M.-C. Pérault Pochat. (2010) Traitement par inhibiteurs sélectifs de la recapture de la sérotonine de la dépression chez la femme enceinte : risques pour le fœtus et le nouveau-né. L'Encéphale 36, D133-D138
CrossRef66
Lee S. Cohen, Betty Wang, Ruta Nonacs, Adele C. Viguera, Elizabeth L. Lemon, Marlene P. Freeman. (2010) Treatment of Mood Disorders During Pregnancy and Postpartum. Psychiatric Clinics of North America 33:2, 273-293
CrossRef67
Andrew J. Lewis, Megan Galbally, Gillian Opie, Anne Buist. (2010) Neonatal growth outcomes at birth and one month postpartum following in utero exposure to antidepressant medication. Australian and New Zealand Journal of Psychiatry 44:5, 482-487
CrossRef68
Robin H. Steinhorn. (2010) Neonatal pulmonary hypertension. Pediatric Critical Care Medicine 11, S79-S84
CrossRef69
Tiffany Field. (2010) Prenatal Depression and Selective Serotonin Reuptake Inhibitors. International Journal of Neuroscience 120:3, 163-167
CrossRef70
Steven H. Abman. (2010) Pulmonary hypertension in children: A historical overview. Pediatric Critical Care Medicine 11, S4-S9
CrossRef71
Marlene P. Freeman, Melinda F. Davis. (2010) Supportive psychotherapy for perinatal depression: preliminary data for adherence and response. Depression and Anxiety 27:1, 39-45
CrossRef72
É. Autret-Leca, H. Cissoko, F. Beau-Salinas, A.-P. Jonville-Bera. 2010. Risque médicamenteux. , 129-135.
CrossRef73
Sengwee Toh, Allen A. Mitchell, Carol Louik, Martha M. Werler, Christina D. Chambers, Sonia Hernández-Díaz. (2009) Antidepressant Use During Pregnancy and the Risk of Preterm Delivery and Fetal Growth Restriction. Journal of Clinical Psychopharmacology 29:6, 555-560
CrossRef74
Deborah R. Kim, Juan Gonzalez, John P. O’Reardon. (2009) Pregnancy and depression: Exploring a new potential treatment option. Current Psychiatry Reports 11:6, 443-446
CrossRef75
L James, S Ito. (2009) Neonatal Pharmacology: Rational Therapeutics for the Most Vulnerable. Clinical Pharmacology & Therapeutics 86:6, 573-577
CrossRef76
Maria Muzik, Sheila M. Marcus, Julie E. Heringhausen, Heather Flynn. (2009) When Depression Complicates Childbearing: Guidelines for Screening and Treatment During Antenatal and Postpartum Obstetric Care. Obstetrics and Gynecology Clinics of North America 36:4, 771-788
CrossRef77
TF Ververs, K van Wensen, MW Freund, M van der Heide, GHA Visser, AFAM Schobben, LTW de Jong-van den Berg, ACG Egberts. (2009) Association between antidepressant drug use during pregnancy and child healthcare utilisation. BJOG: An International Journal of Obstetrics & Gynaecology 116:12, 1568-1577
CrossRef78
Raymond W. Lam, Sidney H. Kennedy, Sophie Grigoriadis, Roger S. McIntyre, Roumen Milev, Rajamannar Ramasubbu, Sagar V. Parikh, Scott B. Patten, Arun V. Ravindran. (2009) Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults.. Journal of Affective Disorders 117, S26-S43
CrossRef79
Kimberly A. Yonkers, Katherine L. Wisner, Donna E. Stewart, Tim F. Oberlander, Diana L. Dell, Nada Stotland, Susan Ramin, Linda Chaudron, Charles Lockwood. (2009) The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. General Hospital Psychiatry 31:5, 403-413
CrossRef80
Amy L. Salisbury, Kathryn L. Ponder, James F. Padbury, Barry M. Lester. (2009) Fetal Effects of Psychoactive Drugs. Clinics in Perinatology 36:3, 595-619
CrossRef81
Cécile Fligny, Sarah Hatia, Pascal Amireault, Jacques Mallet, Francine Côté. (2009) Mammalian prenatal development: the influence of maternally derived molecules. BioEssays 31:9, 935-943
CrossRef82
JENNIFER L. PAYNE, SAMANTHA MELTZER-BRODY. (2009) Antidepressant Use During Pregnancy: Current Controversies and Treatment Strategies. Clinical Obstetrics and Gynecology 52:3, 469-482
CrossRef83
Vimal Kant Sharma, Nagendra Singh Chauhan, Santram Lodhi, A.K. Singhai. (2009) Anti-Depressant Activity of Zizyphus xylopyrus.. International Journal of Phytomedicine 1:1, 12-17
CrossRef84
Fay F. Warnock, Roger Bakeman, Kim Shearer, Shaila Misri, Tim Oberlander. (2009) Caregiving behavior and interactions of prenatally depressed mothers (antidepressant-treated and non-antidepressant-treated) during newborn acute pain. Infant Mental Health Journal 30:4, 384-406
CrossRef85
Nina Boucher, Gideon Koren, Louise Beaulac-Baillargeon. (2009) Maternal Use of Venlafaxine Near Term: Correlation Between Neonatal Effects and Plasma Concentrations. Therapeutic Drug Monitoring 31:3, 404-409
CrossRef86
Naira R. Matevosyan. (2009) Reproductive Health in Women with Serious Mental Illnesses: A Review. Sexuality and Disability 27:2, 109-118
CrossRef87
Jillan Cantor Sackett, Ronald A. Weller, Elizabeth B. Weller. (2009) Selective serotonin reuptake inhibitor use during pregnancy and possible neonatal complications. Current Psychiatry Reports 11:3, 253-257
CrossRef88
Gérald Simonneau, Ivan M. Robbins, Maurice Beghetti, Richard N. Channick, Marion Delcroix, Christopher P. Denton, C. Gregory Elliott, Sean P. Gaine, Mark T. Gladwin, Zhi-Cheng Jing, Michael J. Krowka, David Langleben, Norifumi Nakanishi, Rogério Souza. (2009) Updated Clinical Classification of Pulmonary Hypertension. Journal of the American College of Cardiology 54:1, S43-S54
CrossRef89
G. Ganesh Konduri, U. Olivia Kim. (2009) Advances in the Diagnosis and Management of Persistent Pulmonary Hypertension of the Newborn. Pediatric Clinics of North America 56:3, 579-600
CrossRef90
Sura Alwan, Jan M. Friedman. (2009) Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy. CNS Drugs 23:6, 493-509
CrossRef91
Lakshmi N Yatham, Sidney H Kennedy, Ayal Schaffer, Sagar V Parikh, Serge Beaulieu, Claire O'Donovan, Glenda MacQueen, Roger S McIntyre, Verinder Sharma, Arun Ravindran, L Trevor Young, Allan H Young, Martin Alda, Roumen Milev, Eduard Vieta, Joseph R Calabrese, Michael Berk, Kyooseob Ha, Flávio Kapczinski. (2009) Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disorders 11:3, 225-255
CrossRef92
Susan E. Andrade, Heather McPhillips, David Loren, Marsha A. Raebel, Kimberly Lane, James Livingston, Denise M. Boudreau, David H. Smith, Robert L. Davis, Mary E. Willy, Richard Platt. (2009) Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiology and Drug Safety 18:3, 246-252
CrossRef93
Sheila M. Marcus, Julie E. Heringhausen. (2009) Depression in Childbearing Women: When Depression Complicates Pregnancy. Primary Care: Clinics in Office Practice 36:1, 151-165
CrossRef94
Miles Berger, John A. Gray, Bryan L. Roth. (2009) The Expanded Biology of Serotonin. Annual Review of Medicine 60:1, 355-366
CrossRef95
Kimberly K. McClanahan. (2009) Depression in Pregnant Adolescents: Considerations for Treatment. Journal of Pediatric and Adolescent Gynecology 22:1, 59-64
CrossRef96
SHMUEL DAVIDSON, DIANA PROKONOV, MICHAL TALER, RACHEL MAAYAN, DANIELLA HARELL, IRIT GIL-AD, ABRAHAM WEIZMAN. (2009) Effect of Exposure to Selective Serotonin Reuptake Inhibitors In Utero on Fetal Growth: Potential Role for the IGF-I and HPA Axes. Pediatric Research 65:2, 236-241
CrossRef97
Marco Tuccori, Arianna Testi, Luca Antonioli, Matteo Fornai, Sabrina Montagnani, Narcisa Ghisu, Rocchina Colucci, Tiberio Corona, Corrado Blandizzi, Mario Del Tacca. (2009) Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: A review. Clinical Therapeutics 31, 1426-1453
CrossRef98
Robert Tulloh. (2009) Etiology, Diagnosis, and Pharmacologic Treatment of Pediatric Pulmonary Hypertension. Pediatric Drugs 11:2, 115-128
CrossRef99
Megan Galbally, Andrew J. Lewis, Jarrad Lum, Anne Buist. (2009) Serotonin discontinuation syndrome following in utero exposure to antidepressant medication: prospective controlled study. Australian and New Zealand Journal of Psychiatry 43:9, 846-854
CrossRef100
Julia Raudzus, Shaila Misri. (2009) Managing unipolar depression in pregnancy. Current Opinion in Psychiatry 22:1, 13-18
CrossRef101
C. L. Wichman, K. M. Moore, T. R. Lang, J. L. St. Sauver, R. H. Heise, W. J. Watson. (2009) Congenital Heart Disease Associated With Selective Serotonin Reuptake Inhibitor Use During Pregnancy. Mayo Clinic Proceedings 84:1, 23-27
CrossRef102
Michaël Messaoudi, Jean-François Bisson, Amine Nejdi, Pascale Rozan, Hervé Javelot. (2008) Antidepressant-like effects of a cocoa polyphenolic extract in Wistar–Unilever rats. Nutritional Neuroscience 11:6, 269-276
CrossRef103
Ariela Frieder, Anne L. Dunlop, Larry Culpepper, Peter S. Bernstein. (2008) The clinical content of preconception care: women with psychiatric conditions. American Journal of Obstetrics and Gynecology 199:6, S328-S332
CrossRef104
John H. Coverdale, Laurence B. McCullough, Frank A. Chervenak. (2008) The Ethics of Randomized Placebo-Controlled Trials of Antidepressants With Pregnant Women. Obstetrics & Gynecology 112:6, 1361-1368
CrossRef105
Christina L. Wichman, Amy Fothergill, Katherine M. Moore, Tara R. Lang, Robert H. Heise, William J. Watson. (2008) Recent Trends in Selective Serotonin Reuptake Inhibitor Use in Pregnancy. Journal of Clinical Psychopharmacology 28:6, 714-716
CrossRef106
Nicolas Narboux-Nême, Luigi Michele Pavone, Luigi Avallone, Xiaoxi Zhuang, Patricia Gaspar. (2008) Serotonin transporter transgenic (SERTcre) mouse line reveals developmental targets of serotonin specific reuptake inhibitors (SSRIs). Neuropharmacology 55:6, 994-1005
CrossRef107
Hervé Tixier, Cecile Feyeux, Sophie Girod, Ségoléne Thouvenot, Mathieu Morisse, Serge Douvier, Paul Sagot. (2008) Acute voluntary intoxication with selective serotonin reuptake inhibitors during the third trimester of pregnancy: therapeutic management of mother and fetus. American Journal of Obstetrics and Gynecology 199:5, e9-e12
CrossRef108
Joshua J. Gagne, Vittorio Maio, Vincenzo Berghella, Daniel Z. Louis, Joseph S. Gonnella. (2008) Prescription drug use during pregnancy: a population-based study in Regione Emilia-Romagna, Italy. European Journal of Clinical Pharmacology 64:11, 1125-1132
CrossRef109
Yvonne Dempsie, Margaret R MacLean. (2008) Role of the serotonin transporter in pulmonary arterial hypertension. Expert Review of Clinical Pharmacology 1:6, 749-757
CrossRef110
Patricia A. Brennan, Rebecca Pargas, Elaine F. Walker, Paula Green, D. Jeffrey Newport, Zachary Stowe. (2008) Maternal depression and infant cortisol: influences of timing, comorbidity and treatment. Journal of Child Psychology and Psychiatry 49:10, 1099-1107
CrossRef111
Hendree E. Jones, Peter R. Martin, Sarah H. Heil, Karol Kaltenbach, Peter Selby, Mara G. Coyle, Susan M. Stine, Kevin E. O'Grady, Amelia M. Arria, Gabriele Fischer. (2008) Treatment of opioid-dependent pregnant women: Clinical and research issues. Journal of Substance Abuse Treatment 35:3, 245-259
CrossRef112
Jaques Belik. (2008) Fetal and Neonatal Effects of Maternal Drug Treatment for Depression. Seminars in Perinatology 32:5, 350-354
CrossRef113
R. T. Webb, A. R. Pickles, S. A. King-Hele, L. Appleby, P. B. Mortensen, K. M. Abel. (2008) Parental mental illness and fatal birth defects in a national birth cohort. Psychological Medicine 38:10,
CrossRef114
Bernadette Winklbaur, Nina Kopf, Nina Ebner, Erika Jung, Kenneth Thau, Gabriele Fischer. (2008) Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates. Addiction 103:9, 1429-1440
CrossRef115
Marlene P. Freeman, Melinda Davis, Priti Sinha, Katherine L. Wisner, Joseph R. Hibbeln, Alan J. Gelenberg. (2008) Omega-3 fatty acids and supportive psychotherapy for perinatal depression: A randomized placebo-controlled study. Journal of Affective Disorders 110:1-2, 142-148
CrossRef116
Emily C. Dossett. (2008) Perinatal Depression. Obstetrics and Gynecology Clinics of North America 35:3, 419-434
CrossRef117
Orna Diav-Citrin, Svetlana Shechtman, Dafna Weinbaum, Rebecka Wajnberg, Meytal Avgil, Elena Di Gianantonio, Maurizio Clementi, Corinna Weber-Schoendorfer, Christof Schaefer, Asher Ornoy. (2008) Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. British Journal of Clinical Pharmacology
CrossRef118
Michael P. Carson, Deborah Ehrenthal. (2008) Medical Issues from Preconception Through Delivery: A Roadmap for the Internist. Medical Clinics of North America 92:5, 1193-1225
CrossRef119
Bengt Källén, Petra Otterblad Olausson. (2008) Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiology and Drug Safety 17:8, 801-806
CrossRef120
Bavanisha Vythilingum. (2008) Anxiety disorders in pregnancy. Current Psychiatry Reports 10:4, 331-335
CrossRef121
Orla Conlon, Janine Lynch. (2008) Maternal depression: risk factors and treatment options during pregnancy. The Obstetrician & Gynaecologist 10:3, 151-155
CrossRef122
Gerald Nestadt. (2008) Obsessive-compulsive disorder issues pertinent to women. Women's Health 4:4, 311-313
CrossRef123
Catherine Monk, Kristin L. Leight, Yixin Fang. (2008) The relationship between women’s attachment style and perinatal mood disturbance: implications for screening and treatment. Archives of Women's Mental Health 11:2, 117-129
CrossRef124
Katherine J Gold, Sheila M Marcus. (2008) Effect of maternal mental illness on pregnancy outcomes. Expert Review of Obstetrics & Gynecology 3:3, 391-401
CrossRef125
Anders Engeland, Jørgen G. Bramness, Anne Kjersti Daltveit, Marit Rønning, Svetlana Skurtveit, Kari Furu. (2008) Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106 000 pregnancies in Norway 2004–2006. British Journal of Clinical Pharmacology 65:5, 653-660
CrossRef126
T. F. Oberlander, W. Warburton, S. Misri, J. Aghajanian, C. Hertzman. (2008) Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. The British Journal of Psychiatry 192:5, 338-343
CrossRef127
E. Ramos, M. St-Andre, E. Rey, D. Oraichi, A. Berard. (2008) Duration of antidepressant use during pregnancy and risk of major congenital malformations. The British Journal of Psychiatry 192:5, 344-350
CrossRef128
Peter G. J. ter Horst, Frank G. A. Jansman, Richard A. van Lingen, Jan-Pieter Smit, Lolkje T. W. de Jong-van den Berg, Jacobus R. B. J. Brouwers. (2008) Pharmacological Aspects of Neonatal Antidepressant Withdrawal. Obstetrical & Gynecological Survey 63:4, 267-279
CrossRef129
Michael E. Thase, Timothey Denko. (2008) Pharmacotherapy of Mood Disorders. Annual Review of Clinical Psychology 4:1, 53-91
CrossRef130
Siu Wa Tang, Daiga Helmeste. (2008) Paroxetine. Expert Opinion on Pharmacotherapy 9:5, 787-794
CrossRef131
Kelly M. Chin, Lewis J. Rubin. (2008) Pulmonary Arterial Hypertension. Journal of the American College of Cardiology 51:16, 1527-1538
CrossRef132
Marian K. Bakker, Pieternel Kölling, Paul B. van den Berg, Hermien E. K. de Walle, Lolkje T. W. de Jong van den Berg. (2008) Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. British Journal of Clinical Pharmacology 65:4, 600-606
CrossRef133
Erin Salkeld, Lorraine E. Ferris, David N. Juurlink. (2008) The Risk of Postpartum Hemorrhage With Selective Serotonin Reuptake Inhibitors and Other Antidepressants. Journal of Clinical Psychopharmacology 28:2, 230-234
CrossRef134
Sheila M. Marcus, Heather A. Flynn. (2008) Depression, antidepressant medication, and functioning outcomes among pregnant women. International Journal of Gynecology & Obstetrics 100:3, 248-251
CrossRef135
Gary D. Helmbrecht, Siva Thiagarajah. (2008) Management of Addiction Disorders in Pregnancy. Journal of Addiction Medicine 2:1, 1-16
CrossRef136
Susan E. Andrade, Marsha A. Raebel, Jeffrey Brown, Kimberly Lane, James Livingston, Denise Boudreau, Sharon J. Rolnick, Douglas Roblin, David H. Smith, Mary E. Willy, Judy A. Staffa, Richard Platt. (2008) Use of antidepressant medications during pregnancy: a multisite study. American Journal of Obstetrics and Gynecology 198:2, 194.e1-194.e5
CrossRef137
IWJM van der Horst, I Reiss, D Tibboel. (2008) Therapeutic targets in neonatal pulmonary hypertension: linking pathophysiology to clinical medicine. Expert Review of Respiratory Medicine 2:1, 85-96
CrossRef138
Shauna F. Williams, Jesus R. Alvarez, Helio F. Pedro, Joseph J. Apuzzio. (2008) Glutaric Aciduria Type II and Narcolepsy in Pregnancy. Obstetrics & Gynecology 111:2, Part 2, 522-524
CrossRef139
James P. Rathmell, Christopher M. Viscomi, Marjorie Meyer. 2008. Managing Pain during Pregnancy and Lactation. , 565-584.
CrossRef140
Hiroyuki SAKAKIBARA, Saki YOSHINO, Yoshichika KAWAI, Junji TERAO. (2008) Antidepressant-Like Effect of Onion (Allium cepa L.) Powder in a Rat Behavioral Model of Depression. Bioscience, Biotechnology, and Biochemistry 72:1, 94-100
CrossRef141
CD Chambers, JE Polifka, JM Friedman. (2008) Drug Safety in Pregnant Women and Their Babies: Ignorance Not Bliss. Clinical Pharmacology & Therapeutics 83:1, 181-183
CrossRef142
Stephen Y. Chan, Joseph Loscalzo. (2008) Pathogenic mechanisms of pulmonary arterial hypertension. Journal of Molecular and Cellular Cardiology 44:1, 14-30
CrossRef143
Sophie Grigoriadis. (2008) Doctor please tell me what is best for me and my baby. Expert Review of Obstetrics & Gynecology 3:1, 5-7
CrossRef144
Y. J. Cho, J. Y. Han, J. S. Choi, H. K. Ahn, H. M. Ryu, M. Y. Kim, J. H. Yang, A. A. Nava-Ocampo, G. Koren. (2008) Prenatal multivitamins containing folic acid do not decrease prevalence of depression among pregnant women. Journal of Obstetrics & Gynaecology 28:5, 482-484
CrossRef145
K. Yoshida, H. Yamashita, J. Dayan. 2008. usage des psychotropes durant la grossesse et le post-partum. , 139-169.
CrossRef146
Claudia M. Klier, Nilufar Mossaheb, Alois Saria, Monika Schloegelhofer, Gerald Zernig. (2007) Pharmacokinetics and Elimination of Quetiapine, Venlafaxine, and Trazodone During Pregnancy and Postpartum. Journal of Clinical Psychopharmacology 27:6, 720-722
CrossRef147
François Dubé, Pascal Amireault. (2007) Local serotonergic signaling in mammalian follicles, oocytes and early embryos. Life Sciences 81:25-26, 1627-1637
CrossRef148
Ernest Cutz, Herman Yeger, Jie Pan. (2007) Pulmonary Neuroendocrine Cell System in Pediatric Lung Disease—Recent Advances. Pediatric and Developmental Pathology 10:6, 419-435
CrossRef149
Robert L. Davis, David Rubanowice, Heather McPhillips, Marsha A. Raebel, Susan E. Andrade, David Smith, Marianne Ulcickas Yood, Richard Platt, . (2007) Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiology and Drug Safety 16:10, 1086-1094
CrossRef150
É Ramos, D Oraichi, É Rey, L Blais, A Bérard. (2007) Prevalence and predictors of antidepressant use in a cohort of pregnant women. BJOG: An International Journal of Obstetrics & Gynaecology 114:9, 1055-1064
CrossRef151
Julie L. Mitchell, Jennifer R. Zebrack, Susan L. Davids, Ann B. Nattinger, Joan M. Neuner. (2007) Update in Women’s Health. Journal of General Internal Medicine 22:9, 1351-1364
CrossRef152
T. P. H. Scheffers, J. G. Enk. (2007) Gevolgen ssri-gebruik zwangeren bij de pasgeborene in de eerste 48 uur post partum. Tijdschrift voor kindergeneeskunde 75:4, 159-164
CrossRef153
Bengt Källén. (2007) The safety of antidepressant drugs during pregnancy. Expert Opinion on Drug Safety 6:4, 357-370
CrossRef154
Christina Chambers, Eydie Moses-Kolko, Katherine L Wisner. (2007) Antidepressant use in pregnancy: new concerns, old dilemmas. Expert Review of Neurotherapeutics 7:7, 761-764
CrossRef155
William O. Cooper, Mary E. Willy, Stephen J. Pont, Wayne A. Ray. (2007) Increasing use of antidepressants in pregnancy. American Journal of Obstetrics and Gynecology 196:6, 544.e1-544.e5
CrossRef156
Omar Ali, John Wharton, John Simon Russell Gibbs, Luke Howard, Martin Russell Wilkins. (2007) Emerging therapies for pulmonary arterial hypertension. Expert Opinion on Investigational Drugs 16:6, 803-818
CrossRef157
Katherine L. Wisner, Dorothy K.Y. Sit, Barbara H. Hanusa, Eydie L. Moses-Kolko, James M. Perel. (2007) Reply to Drs Henderson and Vale. Journal of Clinical Psychopharmacology 27:3, 322-325
CrossRef158
Salvador Vale. (2007) Preventing Postpartum Complications in the Depressed Pregnant Women. Journal of Clinical Psychopharmacology 27:3, 321-322
CrossRef159
Xènia Ramió, Cristina Aguilera. (2007) Antidepresivos inhibidores selectivos de la recaptación de serotonina durante el embarazo. Medicina Clínica 129:5, 194-196
CrossRef160
Linda H. Chaudron. (2007) Treating Pregnant Women with Antidepressants: The Gray Zone. Journal of Women's Health 16:4, 551-553
CrossRef161
Monique B. Kelly, Katherine L. Wisner, Marie D. Cornelius. (2007) SSRIs and Birth Defects. Epidemiology 18:3, 411-412
CrossRef162
Consuelo Mejías, Elvira Rodríguez-Pinilla, Paloma Fernández Martín, María Luisa Martínez-Frías. (2007) Efectos adversos de los inhibidores selectivos de la recaptación de serotonina durante el tercer trimestre de la gestación y guías de prevención. Medicina Clínica 128:15, 584-589
CrossRef163
Wing Hung Tam, Tony Chung. (2007) Psychosomatic disorders in pregnancy. Current Opinion in Obstetrics and Gynecology 19:2, 126-132
CrossRef164
Cynthia M Way. (2007) Safety of Newer Antidepressants in Pregnancy. Pharmacotherapy 27:4, 546-552
CrossRef165
Isabelle Lacroix, Caroline Hurault, Sylvie Saivin, Valérie Raoul, Alain Berrebi, Emmanuelle Souchet, Karine Desboeuf, Jean-Louis Montastruc, Christine Damase-Michel. (2007) Exposition in utero à des substances psychoactives : résultats de l'étude "NENUPHAR". Thérapie 62:2, 177-183
CrossRef166
Darren B. Taichman, Jess Mandel. (2007) Epidemiology of Pulmonary Arterial Hypertension. Clinics in Chest Medicine 28:1, 1-22
CrossRef167
Lacramioara Spetie, L. Eugene Arnold. (2007) Ethical issues in child psychopharmacology research and practice: emphasis on preschoolers. Psychopharmacology 191:1, 15-26
CrossRef168
Chi-Un Pae, Ashwin A Patkar. (2007) Paroxetine: current status in psychiatry. Expert Review of Neurotherapeutics 7:2, 107-120
CrossRef169
A L Potts, K L Young, B S Carter, J P Shenai. (2007) Necrotizing enterocolitis associated with in utero and breast milk exposure to the selective serotonin reuptake inhibitor, escitalopram. Journal of Perinatology 27:2, 120-122
CrossRef170
K. J. Looper. (2007) Potential Medical and Surgical Complications of Serotonergic Antidepressant Medications. Psychosomatics 48:1, 1-9
CrossRef171
J.A. Stockman. (2007) Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn. Yearbook of Pediatrics 2007, 383-384
CrossRef172
Salvatore Gentile. (2007) Serotonin Reuptake Inhibitor-Induced Perinatal Complications. Pediatric Drugs 9:2, 97-106
CrossRef173
LISA O'BRIEN, ANNE-MARIE SCHACHTSCHNEIDER, GIDEON KOREN, JOHN H. WALKER, ADRIENNE EINARSON. (2007) Longitudinal Study of Depression, Anxiety, Irritability, and Stress in Pregnancy Following Evidence-Based Counseling on the Use of Antidepressants. Journal of Psychiatric Practice 13:1, 33-39
CrossRef174
Golde G. Dudell, Lucky Jain. (2006) Hypoxic Respiratory Failure in the Late Preterm Infant. Clinics in Perinatology 33:4, 803-830
CrossRef175
Tessa Ververs, Hans Kaasenbrood, Gerard Visser, Fred Schobben, Lolkje Jong-van den Berg, Toine Egberts. (2006) Prevalence and patterns of antidepressant drug use during pregnancy. European Journal of Clinical Pharmacology 62:10, 863-870
CrossRef176
Stephen L Archer, Evangelos D Michelakis. (2006) An evidence-based approach to the management of pulmonary arterial hypertension. Current Opinion in Internal Medicine 5:5, 453-460
CrossRef177
(2006) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 15:8, i-xii
CrossRef178
H. R. Vries. (2006) Antidepressiva en foetale longafwijkingen. Medisch-Farmaceutische Mededelingen 44:7, 203-204
CrossRef179
Emily Feinberg, Megan V. Smith, Melody Johnson Morales, Angelika H. Claussen, D. Camille Smith, Ruth Perou. (2006) Improving Women's Health during Internatal Periods: Developing an Evidenced-Based Approach to Addressing Maternal Depression in Pediatric Settings. Journal of Women's Health 15:6, 692-703
CrossRef180
(2006) Selective Serotonin-Reuptake Inhibitors and Persistent Pulmonary Hypertension of the Newborn. New England Journal of Medicine 354:20, 2188-2190
Full Text181
&NA;. (2006) Antidepressants During Pregnancy. AJN, American Journal of Nursing 106:5, 43
CrossRef182
Joyce A. Generali. (2006) Hospital Pharmacy Pulse - Recent Publications on Medications and Pharmacy. Hospital Pharmacy 41:5, 484-486
CrossRef183
Robert Tulloh. (2006) Management and therapeutic options in pediatric pulmonary hypertension. Expert Review of Cardiovascular Therapy 4:3, 361-374
CrossRef184
Mills, James L., . (2006) Depressing Observations on the Use of Selective Serotonin-Reuptake Inhibitors during Pregnancy. New England Journal of Medicine 354:6, 636-638
Full Text185
Hiroyuki Sakakibara, Kaori Ishida, Oliver Grundmann, Jun-ichiro Nakajima, Shujiro Seo, Veronika Butterweck, Yuko Minami, Satomi Saito, Yoshichika Kawai, Yutaka Nakaya, Junji Terao. (2006) Antidepressant Effect of Extracts from Ginkgo biloba Leaves in Behavioral Models. Biological & Pharmaceutical Bulletin 29:8, 1767-1770
CrossRef
- Letters
